Skip to content

Serotonin: all studies

Page 354 of 400: studies 3,531 to 3,540 of 3,999, newest first. Back to the serotonin overview

Research

The novel neurotensin analog NT69L blocks phencyclidine (PCP)-induced increases in locomotor activity and PCP-induced increases in monoamine and amino acids levels in the medial prefrontal cortex

Brain Research November 27, 2009 Zhimin Li, M. Boules, Katrina Williams et al.

Schizophrenia is a life-long, severe, and disabling brain disorder that requires chronic pharmacotherapy. Because current antipsychotic drugs do not provide optimal therapy, we have been developing novel treatments that focus on receptors for the neuropeptide neurotensin (NT). NT69L, an analog of neurotensin(8–13), acts like an atypical antipsychotic drug in several dopamine-based animal models...

Discriminative stimulus effects of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM), ketanserin, and (R)-(+)-{alpha}-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-pipidinemethanol (MDL100907) in rats.

Journal of Pharmacology and Experimental Therapeutics November 2009 Jun-Xu Li, Alison Unzeitig, Martin A Javors et al.

Very little is known about constitutive activity in vivo. This study examined whether constitutive activity and inverse agonism contribute to discriminative stimulus effects of drugs acting at serotonin (5-HT)(2A) receptors. Rats were trained to discriminate between saline and either 0.56 mg/kg 5-HT(2) receptor agonist 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM), 1.0 mg/kg 5-HT(2A)...

Glutamate-based antidepressants: 20 years on.

Trends in pharmacological sciences November 2009 Phil Skolnick, Piotr Popik, Ramon Trullas

Depression is a chronic recurring illness that affects more than 120 million people worldwide. Drugs increasing the synaptic availability of serotonin and norepinephrine (biogenic amine-based agents) have been used to treat depression for more than 50 years. However, significant symptom improvement requires > or =2-4 weeks of treatment and a first course of therapy provides symptom relief to...

Cognitive effects of psychotomimetic drugs in rats discriminating number cues.

Psychopharmacology November 1, 2009 C B Willmore, D M Krall, F M Spears et al.

Deficits in memory and attention are broadly acknowledged during psychosis; however, experiments on modeled psychosis often test working memory without systematic manipulation of attentional demands. The major research goal was discovering which neurobehavioral processes, attention, or memory contributed more to drug-provoked performance deficits. Rats were trained to perform operant ratio...

Discriminative stimulus effects of psychostimulants and hallucinogens in S(+)-3,4-methylenedioxymethamphetamine (MDMA) and R(-)-MDMA trained mice.

Journal of Pharmacology and Experimental Therapeutics November 1, 2009 Kevin S. Murnane, Naoki Murai, Leonard L. Howell et al. 34 citations

3,4-Methylenedioxymethamphetamine (MDMA) is a substituted phenethylamine more commonly known as the drug of abuse "ecstasy." The acute and persistent neurochemical effects of MDMA in the mice are distinct from those in other species. MDMA shares biological effects with both amphetamine-type stimulants and mescaline-type hallucinogens, which may be attributable to distinct effects of its two...

Emerging role of glutamate in the pathophysiology of major depressive disorder.

Brain Research Reviews October 2009 Kenji Hashimoto

Major depressive disorder (MDD) is a common, chronic, recurrent mental illness that affects millions of individuals worldwide. To date, the monoaminergic systems (serotonin, norepinephrine, and dopamine) have received the most attention in the neurobiology of MDD, and all classes of antidepressants target these monoaminergic systems. Accumulating evidence suggests that the glutamatergic system...

Neuroendocrine and subjective responses to pharmacological challenge with citalopram: a controlled study in male and female ecstasy/MDMA users.

Journal of Psychopharmacology September 2009 K Allott, B K Canny, J H Broadbear et al.

Despite evidence that +/-3,4-methylenedioxymethamphetamine (MDMA; 'ecstasy') causes persistent alterations to the serotonergic system of animals, evidence for long-term neurological effects of ecstasy/MDMA in humans remains equivocal. The current study assessed serotonin functioning of nine male and 11 female recreational ecstasy polydrug users by measuring neuroendocrine (prolactin, cortisol)...

Drug-induced fibrotic valvular heart disease.

The Lancet August 15, 2009 Sanjeev Bhattacharyya, Anthony H Schapira, Dimitri P Mikhailidis et al.

The initial association between the development of valvular heart disease and drugs stems from observations made during the use of methysergide and ergotamine for migraine prophylaxis in the 1960s. Since then, the appetite suppressants fenfluramine and dexfenfluramine, the dopamine agonists pergolide and cabergoline, and more recently, the recreational drug ecstasy (3,4...

Differential changes in mesolimbic dopamine following contingent and non-contingent MDMA self-administration in mice.

Psychopharmacology August 2009 María Juliana Orejarena, Fernando Berrendero, Rafaël Maldonado et al.

There is evidence demonstrating changes in dopamine (DA) transmission in the nucleus accumbens (NAc) related to contingent versus non-contingent drug administration. The aim of this study was to evaluate basal and 3,4-methylenedioxymethamphetamine (MDMA)-stimulated DA levels in the NAc of mice that had previously received contingent and non-contingent infusions of MDMA. Contingent mice were...

Equivalent effects of acute tryptophan depletion on REM sleep in ecstasy users and controls.

Psychopharmacology July 8, 2009 Robin Carhart-Harris, David Nutt, Marcus R. Munafò et al.

Introduction: This study sought to test the association between 3,4-methylenedioxymethamphetamine use, serotonergic function and sleep. Materials and methods: Ambulatory polysomnography was used to measure three nights sleep in 12 ecstasy users and 12 controls after screening (no intervention), a tryptophan-free amino acid mixture (acute tryptophan depletion (ATD)) and a tryptophan-supplemented...

DOI: 10.1007/s00213-009-1595-3 (opens in new tab) Full text (opens in new tab) Humans Substance-related disorders N-methyl-3,4-methylenedioxyamphetamine Tryptophan +9